20050506
 Johnson & Johnson: FDA Panel's Vote Is Setback For Leukemia Drug Zarnestra   The Wall Street Journal,  May 6, 2005  A Food and Drug advisory panel voted against recommending that the agency approve a proposed Johnson & Johnson drug aimed at treating a certain type of leukemia in elderly patients.   
